Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nurix Therapeutics, Inc. (Nasdaq: NRIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on targeted protein degradation medicines, Nurix uses its 10-K, 10-Q and 8-K reports to describe pipeline progress, financing activities, collaborations and governance matters.
Recent Form 8-K filings illustrate the types of information NRIX investors can monitor here. One 8-K details an underwriting agreement for a registered offering of common stock under a shelf registration statement, including intended uses of proceeds such as funding clinical development of the BTK degrader bexobrutideg in chronic lymphocytic leukemia, exploring autoimmune indications, expanding the research pipeline and supporting general corporate purposes. Other 8-Ks report on the initiation of the pivotal DAYBreak Phase 2 study of bexobrutideg in relapsed or refractory CLL/SLL, updated clinical data for NX-1607, and changes to the board of directors and committee roles.
Through this page, users can review current and historical SEC documents related to Nurix’s common stock listed on the Nasdaq Global Market under the symbol NRIX. Filings may cover topics such as results of operations, equity offerings, clinical development milestones, collaboration agreements with partners like Gilead, Sanofi and Pfizer, and appointments or resignations of directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand material events without reading every page. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K and other forms appear promptly, while dedicated sections make it easier to locate items related to capital raises, clinical trial disclosures or governance changes. For those tracking insider activity, Form 4 and related ownership filings can also be accessed to see how Nurix’s insiders transact in NRIX shares.
Nurix Therapeutics (NRIX) Form 4: Chief Financial Officer Hans van Houte reported RSU-to-share conversions and a tax-related sale on 10/30/2025. Multiple RSU tranches converted to common stock at no cost: 2,886, 2,000, 3,750, and 2,858 shares. To cover withholding taxes tied to these vestings, he executed a mandated “sell-to-cover” of 3,130 shares at a weighted average price of $12.7967.
Following these transactions, he beneficially owned 43,876 shares of common stock directly. The RSUs vest quarterly under existing schedules, and each RSU represents the right to receive one share upon vesting.
Nurix Therapeutics (NRIX) reported insider activity by its Chief Legal Officer, Christine Ring. On 10/30/2025, multiple restricted stock unit (RSU) vestings converted into common stock via code “M” totaling 10,532 shares (1,924; 2,000; 3,750; 2,858), each at $0 per the RSU terms. A subsequent sale of 3,644 shares at a weighted average price of $12.7967 was executed to cover tax withholding obligations under a required “sell-to-cover” arrangement.
Following these transactions, the reporting person held 50,897 shares directly. Each RSU represents a right to receive one share upon vesting, with tranches vesting quarterly pursuant to previously granted awards.
Nurix Therapeutics (NRIX) reported an insider transaction by its Chief Scientific Officer on Form 4. On 10/30/2025, multiple restricted stock unit (RSU) vestings were settled into common stock, including 3,207; 2,000; 3,750; and 2,858 shares at $0 per share. The insider also sold 4,087 shares at a weighted average price of $12.7967 to satisfy tax withholding via a mandated “sell to cover.” Following these transactions, the insider directly owned 76,751 shares.
Nurix Therapeutics (NRIX) filed a Form 4 reporting an equity grant to its Chief Scientific Officer. On 10/14/2025, the reporting person received 20,000 restricted stock units (RSUs), each representing a right to receive one share of Nurix common stock.
The RSUs were reported at a price of $0 for the derivative security and are held as direct ownership. The award will vest on the second anniversary of the date of grant, contingent on continuous service through that date, after which shares will be delivered. RSUs do not have an expiration date; they either vest or are canceled prior to vesting.
Nurix Therapeutics (NRIX) launched a primary offering of 24,485,799 shares of common stock at a public offering price of $10.21 per share. The transaction implies a gross offering amount of $250,000,007.79, underwriting discounts and commissions of $15,000,000.47, and proceeds to Nurix before expenses of $235,000,007.32. The company estimates net proceeds of approximately $234.3 million after offering expenses.
Nurix plans to use the cash to fund clinical development, including bexobrutideg in CLL and potential autoimmune indications, expand R&D, and for working capital and general corporate purposes; it may also consider in-licensing or acquisitions. Based on its plans, management states this funding, combined with existing cash and investments, supports operations into 2028.
J.P. Morgan, Jefferies, and Stifel are joint bookrunners; delivery is expected on or about October 23, 2025. Shares outstanding will be 101,358,485 immediately after the offering. Shares outstanding were 76,872,686 as of August 31, 2025. The filing notes immediate dilution of $4.23 per share at the $10.21 offering price. Directors and officers, and the company, agreed to a 60‑day lock-up, subject to customary exceptions.
Nurix Therapeutics announced an underwritten public offering, agreeing to issue and sell 24,485,799 shares of common stock at an offering price of $10.21 per share. The company estimates net proceeds of approximately $234.3 million after underwriting discounts, commissions, and expenses.
Nurix plans to use the proceeds primarily to fund clinical development of its drug candidates, including the clinical development of bexobrutideg in chronic lymphocytic leukemia and for potential autoimmune indications, as well as broader R&D, working capital, and general corporate purposes. The offering is being conducted under the company’s shelf registration statement on Form S-3 and a related prospectus supplement, with J.P. Morgan, Jefferies, and Stifel acting as representatives of the underwriters.
Nurix Therapeutics (NRIX) announced initiation of the DAYBreak Phase 2 trial of bexobrutideg (NX-5948), a pivotal single-arm study in relapsed/refractory CLL/SLL. The study will enroll approximately 100 patients whose disease progressed after a covalent BTK inhibitor, a non-covalent BTK inhibitor, and a BCL-2 inhibitor. The primary endpoint is objective response rate per iwCLL criteria assessed by an independent review committee, and the first site was activated in
The company selected a 600 mg once-daily dose based on Phase 1b data and alignment with U.S., U.K., and EU regulators, and plans a global randomized Phase 3 confirmatory trial in the first half of
Nurix Therapeutics (NRIX) is a clinical-stage company focused on targeted protein degradation with partnered discovery programs and wholly owned BTK and CBL-B programs. For the nine months ended August 31, 2025 the company reported a net loss of
Collaboration and license activity remain a primary source of revenue: license revenue of
Nurix Therapeutics, Inc. filed a Form 8-K to report that it issued a press release announcing its financial results for the fiscal quarter ended August 31, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference. The company states that the information under Item 2.02, including Exhibit 99.1, is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal liability purposes.
Nurix Therapeutics director Julia P. Gregory reported a transaction on 09/17/2025 showing acquisition of 10,750 shares of common stock. The filing indicates a director stock option with an exercise/conversion price of $1.86 was exercised (transaction code M), resulting in 10,750 shares acquired and 10,750 shares owned following the transaction. The option covers the right to buy 10,750 shares and lists an expiration date of 12/22/2029. The filing notes the option vested monthly beginning September 12, 2019 and fully vested on August 12, 2023.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
